Cibus, Inc. (CBUS)
After hours:
| Previous Close | 17.85 |
| Open | 18.04 |
| Bid | 17.53 x 100 |
| Ask | 17.94 x 100 |
| Day's Range | 17.40 - 18.18 |
| 52 Week Range | 8.90 - 38.85 |
| Volume | |
| Avg. Volume | 66,760 |
| Market Cap | 442.556M |
| Beta (5Y Monthly) | 2.00 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -25.95 |
| Earnings Date | Aug 07, 2024 - Aug 12, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 23.00 |
GlobeNewswireCibus Reports First Quarter Financial Results and Provides Business Update
Important EU Parliament vote on gene editing continues global momentum for the approval of new genomic techniques (NGTs) as similar to conventional breeding Completed single cell regeneration platform for Wheat – with Canola & Rice, Cibus now has its semi-automated crop platform operational for 3 of the top 5 major crops Signed three agreements in Rice including with Loveland Products Inc., a subsidiary of Nutrien Ltd., and Interoc S.A., for Cibus' two proprietary Herbicide Tolerance traits (HT1
Simply Wall St.Cibus, Inc.'s (NASDAQ:CBUS) top owners are individual investors with 53% stake, while 26% is held by institutions
Key Insights Cibus' significant individual investors ownership suggests that the key decisions are influenced by...
- GlobeNewswire
Cibus to Report First Quarter 2024 Financial Results on May 9, 2024 and Host Conference Call
SAN DIEGO, April 25, 2024 (GLOBE NEWSWIRE) -- Cibus, Inc. (Nasdaq: CBUS), a leading agricultural biotechnology company that uses proprietary gene editing technologies to develop plant traits (or specific genetic characteristics) in seeds, today announced that the company will report first quarter 2024 financial results on Thursday, May 9, 2024. Cibus’ management team will host a conference call and audio webcast at 4:30 p.m. ET on that day to discuss the financial results and other company updat
